keyword
MENU ▼
Read by QxMD icon Read
search

Hiv statin

keyword
https://www.readbyqxmd.com/read/28265887/coronary-artery-disease-in-hiv-infected-patients-downside-of-living-longer
#1
REVIEW
John Charles A Lacson, Revery P Barnes, Hossein Bahrami
PURPOSE OF REVIEW: Introduction of combination antiretroviral therapy (ART) has increased the life expectancy of patients with HIV infection, allowing them to live longer with this chronic medical condition and consequently experiencing conditions such as cardiovascular diseases (CVDs). Several studies have investigated the increased risk of CVD in people living with HIV (PLWH). However, less is known about the exact mechanisms involved in this increased risk. Also, specific guidelines for management of CVD in PLWH have not been developed yet...
April 2017: Current Atherosclerosis Reports
https://www.readbyqxmd.com/read/28252528/effects-of-pitavastatin-and-pravastatin-on-markers-of-immune-activation-and-arterial-inflammation-in-hiv
#2
Mabel Toribio, Kathleen V Fitch, Laura Sanchez, Tricia H Burdo, Kenneth C Williams, Craig A Sponseller, Mary McCurdy Pate, Judith A Aberg, Markella V Zanni, Steven K Grinspoon
OBJECTIVE: Persistent immune activation is thought to contribute to increased cardiovascular disease risk in HIV and statins may help modulate systemic immune activation. We aimed to compare the effects of two key statins on markers of systemic immune activation and arterial inflammation in the HIV population. DESIGN: Double-blind, active-controlled, parallel-group comparative trial performed in 45 sites. METHODS: Two hundred and fifty-two antiretroviral therapy-treated HIV-infected participants with dyslipidemia were randomized (1 : 1) to pitavastatin 4 mg daily vs...
March 27, 2017: AIDS
https://www.readbyqxmd.com/read/28249009/current-use-of-statins-reduces-risk-of-hiv-rebound-on-suppressive-haart
#3
Henning Drechsler, Colby Ayers, James Cutrell, Naim Maalouf, Pablo Tebas, Roger Bedimo
BACKGROUND: Despite compelling evidence for activity against HIV-1 in vitro, a virologic effect of statins has not been shown in clinical studies. Given their short plasma half-lives, such an effect may be transient and only apparent during ongoing exposure. METHODS: We studied all HIV infected US-Veterans who started HAART 1995-2011, had a documented HIV viral load (VL) >1000 copies/mL, reached an undetectable VL on HAART, and had ≥1 follow-up VL within 13 months...
2017: PloS One
https://www.readbyqxmd.com/read/28208120/cardiovascular-complications-of-hiv-infection
#4
Marshall J Glesby
HIV-infected individuals are at increased risk for cardiovascular events. Widely used cardiovascular disease (CVD) risk calculators to determine indications for statin treatment are not well validated for use in the HIV-infecte population. Some experts advocate including HIV infection as an independent risk factor for CVD. The effects of antiretroviral therapy on lipid profiles and the potentially increased risk for cardiovascular events must be taken into account when selecting treatment for HIV-infected individuals...
December 2017: Topics in Antiviral Medicine
https://www.readbyqxmd.com/read/28182617/statins-in-hiv-infected-patients-potential-beneficial-effects-and-clinical-use
#5
Enrique Bernal, Mar Masiá, Irene Marín, Félix Gutiérrez
Patients living with HIV have an increased risk of cardiovascular disease that is considered to be the result of an interaction between traditional cardiovascular risk factors, particularly smoking and dyslipidemia, and persistent chronic inflammation and immune activation associated with HIV infection, along with side effects of antiretroviral therapy. In the general population, the administration of statins has been associated with a reduction in cardiovascular disease-associated mortality, and these drugs are among the most common class of medication prescribed in high-income countries...
February 9, 2017: AIDS Reviews
https://www.readbyqxmd.com/read/28121706/greater-remnant-lipoprotein-cholesterol-reduction-with-pitavastatin-compared-to-pravastatin-in-hiv-infected-patients-the-intrepid-trial
#6
Parag H Joshi, P Elliott Miller, Seth S Martin, Steven R Jones, Joseph M Massaro, Ralph B D'Agostino, Krishnaji R Kulkarni, Craig Sponseller, Peter P Toth
OBJECTIVE: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in those with HIV. An emerging CVD risk factor is triglyceride-rich remnant lipoprotein cholesterol (RLP-C: the sum of intermediate-density lipoprotein and very low-density lipoprotein3 cholesterol). The effects of statin therapy on lipoprotein subfractions, including RLP-C, in HIV-dyslipidemia are unknown. METHODS: This is a post-hoc analysis of the randomized INTREPID trial (NCT 01301066) comparing pitavastatin 4 mg daily vs...
January 24, 2017: AIDS
https://www.readbyqxmd.com/read/28072892/use-of-statins-and-aspirin-to-prevent-cardiovascular-disease-among-hiv-positive-patients-a-survey-among-italian-hiv-physicians
#7
Paolo Maggi, Giuseppe Vittorio De Socio, Stefania Cicalini, Maurizio D'Abbraccio, Gabriella D'Ettorre, Antonio Di Biagio, Canio Martinelli, Giuseppe Nunnari, Stefano Rusconi, Laura Sighinolfi, Vincenzo Spagnuolo, Nicola Squillace
We conducted a survey among Italian HIV specialists to study the utilization of statins and aspirin, administering a questionnaire aimed at investigating their use, the use of guidelines and scores, and the management of interactions. The answers were uniform in the different geographic areas. The majority directly prescribe statins and 43% of them prescribe aspirin. The majority follows guidelines and utilize scores to calculate the CV risk. Our survey demonstrates the commitment and autonomy in prescribing statins and aspirin of Italian physicians...
January 10, 2017: New Microbiologica
https://www.readbyqxmd.com/read/28062146/intensive-statin-regimens-for-reducing-risk-of-cardiovascular-diseases-among-human-immunodeficiency-virus-infected-population-a-nation-wide-longitudinal-cohort-study-2000-2011
#8
Huang-Tz Ou, Kai-Cheng Chang, Chung-Yi Li, Chen-Yi Yang, Nai-Ying Ko
OBJECTIVE: This study evaluated the risk of cardiovascular diseases (CVD) in a statin-treated HIV-infected population and the effects of intensive statin regimens (i.e., high-dose or potency) on CVD risks. METHODS: 945 HIV-infected patients newly on statin treatment (144, 15.7% with CVD history) were identified from Taiwan's national HIV cohort. Using the median of the first year cumulative statin dosage as a cut-off point, patients were classified into either a high-dose or low-dose group...
March 1, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28061820/associations-of-statins-and-antiretroviral-drugs-with-the-onset-of-type-2-diabetes-among-hiv-1-infected-patients
#9
Vincenzo Spagnuolo, Laura Galli, Andrea Poli, Stefania Salpietro, Nicola Gianotti, Piermarco Piatti, Francesca Cossarini, Concetta Vinci, Elisabetta Carini, Adriano Lazzarin, Antonella Castagna
BACKGROUND: Statin use is associated with a modest increase in the incidence of type 2 diabetes mellitus (DM) among the general population. However, HIV-infected patients have a higher risk of developing DM, and it is unclear whether statins have a diabetogenic effect in these patients. Therefore, we investigated the associations of statin use and exposure to antiretroviral drugs with type 2 DM onset in a cohort of HIV-infected patients. METHODS: This retrospective, controlled, cohort study identified HIV-1-infected patients who did not have DM and were not receiving statins at their antiretroviral treatment (ART) initiation...
January 7, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28060020/significant-association-between-statin-associated-myalgia-and-vitamin-d-deficiency-among-treated-hiv-infected-patients
#10
Leonardo Calza, Eleonora Magistrelli, Vincenzo Colangeli, Marco Borderi, Ilaria Contadini, Isabella Bon, Maria Carla Re, Pierluigi Viale
BACKGROUND: Several studies have shown a significant association between vitamin D deficiency and an increased risk of statin-related symptomatic myalgia in the general population, but there are no data among HIV-infected persons. METHODS: A retrospective, cohort study was conducted to assess the incidence of symptomatic myalgia and elevation in serum creatine kinase level among HIV-positive adults on combination antiretroviral therapy and treated with atorvastatin or rosuvastatin for at least 12 months between 2011 and 2015 in our outpatient unit...
March 13, 2017: AIDS
https://www.readbyqxmd.com/read/28045766/baseline-vitamin-d-deficiency-decreases-the-effectiveness-of-statins-in-hiv-infected-adults-on-antiretroviral-therapy
#11
Corrilynn O Hileman, Vin Tangpricha, Abdus Sattar, Grace A McComsey
OBJECTIVE: Vitamin D deficiency is common in HIV. Statins may increase vitamin D, and it is unknown whether vitamin D modifies the effect of statins on cardiovascular disease. DESIGN: SATURN-HIV was a 96-week, randomized, placebo-controlled trial designed to evaluate the effect of rosuvastatin on immune activation and subclinical vascular disease in HIV-infected adults on antiretroviral therapy. This analysis focuses on the prespecified secondary endpoint 25-hydroxyvitamin D [25(OH)D] concentrations...
April 15, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/28011249/lack-of-effects-of-statins-on-high-density-lipoprotein-subfractions-in-hiv-1-infected-patients-receiving-protease-inhibitors
#12
Randa Bittar, Élisabeth Aslangul, Philippe Giral, Lambert Assoumou, Marc-Antoine Valantin, Olga Kalmykova, Marie-Christine Federspiel, Corinne Cherfils, Dominique Costagliola, Dominique Bonnefont-Rousselot
BACKGROUND: We evaluated the effect of 45 days of rosuvastatin or pravastatin treatment on the distribution of HDL subfractions in HIV-1-infected individuals receiving boosted protease inhibitors (PIs) with cardiovascular risk. METHODS: The distribution of HDL subclasses by gradient gel electrophoresis was blindly assessed in 74 HIV-1-infected individuals receiving boosted PIs at baseline and at day 45 of statin treatment, and compared with the distribution obtained in 63 healthy normolipidemic individuals taken as controls...
February 2017: Comptes Rendus Biologies
https://www.readbyqxmd.com/read/28002550/assessing-and-refining-myocardial-infarction-risk-estimation-among-patients-with-human-immunodeficiency-virus-a-study-by-the-centers-for-aids-research-network-of-integrated-clinical-systems
#13
Matthew J Feinstein, Robin M Nance, Daniel R Drozd, Hongyan Ning, Joseph A Delaney, Susan R Heckbert, Matthew J Budoff, William C Mathews, Mari M Kitahata, Michael S Saag, Joseph J Eron, Richard D Moore, Chad J Achenbach, Donald M Lloyd-Jones, Heidi M Crane
Importance: Persons with human immunodeficiency virus (HIV) that is treated with antiretroviral therapy have improved longevity but face an elevated risk of myocardial infarction (MI) due to common MI risk factors and HIV-specific factors. Despite these elevated MI rates, optimal methods to predict MI risks for HIV-infected persons remain unclear. Objective: To determine the extent to which existing and de novo estimation tools predict MI in a multicenter HIV cohort with rigorous MI adjudication...
February 1, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/27979047/statin-therapy-and-low-density-lipoprotein-cholesterol-reduction-in-hiv-infected-individuals-after-acute-coronary-syndrome-results-from-the-pacs-hiv-lipids-substudy
#14
Franck Boccara, Joe Miantezila Basilua, Murielle Mary-Krause, Sylvie Lang, Emmanuel Teiger, Philippe Gabriel Steg, Christian Funck-Brentano, Pierre-Marie Girard, Dominique Costagliola, Ariel Cohen, Marguerite Guiguet
Knowledge about lipid interventions in secondary prevention in HIV-infected individuals is limited; studies are sparse. METHODS: A prospective observational multicenter study enrolled 282 patients on statin 1 month after first acute coronary syndrome (ACS) (95 HIV-infected individuals, 187 HIV-uninfected). Data on fasting lipids (total cholesterol [TC], low-density lipoprotein cholesterol, high-density lipoprotein cholesterol [HDL-C], non-HDL-C, triglycerides, TC/HDL-C ratio) were collected over 3 years...
January 2017: American Heart Journal
https://www.readbyqxmd.com/read/27872071/results-of-a-doravirine-atorvastatin-drug-drug-interaction-study
#15
Sauzanne Khalilieh, Ka Lai Yee, Rosa I Sanchez, Ilias Triantafyllou, Li Fan, Noha Maklad, Heather Jordan, Maureen Martell, Marian Iwamoto
Doravirine is a novel, highly potent, nonnucleoside reverse transcriptase inhibitor that is administered once daily and that is in development for the treatment of HIV-1 infection. In vitro and clinical data suggest that doravirine is unlikely to cause significant drug-drug interactions via major drug-metabolizing enzymes or transporters. As a common HIV-1 infection comorbidity, hypercholesterolemia is often treated with statins, including the commonly prescribed atorvastatin. Atorvastatin is subject to drug-drug interactions with cytochrome P450 3A4 (CYP3A4) inhibitors...
February 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27831597/pharmacological-management-of-dyslipidemia-in-high-and-very-high-cardiovascular-risk-patients
#16
V Pascual Fuster
Dyslipaemia is one of the main risk factors in the development of cardiovascular diseases. Currently, there are different alternatives available (amongst which statins occupy a pre-eminent place), to optimise the treatment of patients at high or very high cardiovascular risk. Despite this, the percentage of patients that achieve good lipid control is low. The causes of the mismatch with proposed objectives include lack of patient adherence and therapeutic inertia. This review uses available evidence and the latest clinical guides as a basis to assess the pharmacological treatment of dyslipaemia in patients with a background of arteriosclerotic vascular disease, diabetes, chronic kidney disease, cardiovascular risk at ≥5% calculated by SCORE and familial hypercholesterolaemia...
December 2016: Revista Española de Sanidad Penitenciaria
https://www.readbyqxmd.com/read/27822971/drug-induced-liver-injury-is-chronic-liver-disease-a-risk-factor-and-a-clinical-issue
#17
Rolf Teschke, Gaby Danan
Clinicians and practitioners caring for patients with chronic liver disease are often unsure whether drug therapy is a hazard that increases their patient's risk for drug-induced liver injury (DILI). Areas covered: We searched for reports of drug induced liver injury, both idiosyncratic and intrinsic, in patients with chronic liver disease including non-alcoholic and alcoholic liver disease, and cirrhosis. Reports we analyzed include statin treatment in patients with fatty liver, acetaminophen use in alcoholic fatty liver, antituberculous drugs in patients with tuberculosis and viral hepatitis, antiviral medications in hepatitis and antiretroviral medications in HIV/AIDS...
November 8, 2016: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/27753678/statin-drugs-decrease-progression-to-cirrhosis-in-hiv-hepatitis-c-virus-coinfected-individuals
#18
Nora T Oliver, Christine M Hartman, Jennifer R Kramer, Elizabeth Y Chiao
INTRODUCTION: Chronic HIV/hepatitis C virus (HCV) coinfection carries increased risk of cirrhosis, hepatocellular carcinoma, and death. Due to anti-inflammatory properties, 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) inhibitors (statins) may be useful adjunctive therapy to reduce liver disease progression. METHODS: Clinical information was extracted from the Veterans Affairs HIV and HCV Clinical Case Registries (1999-2010). HIV-related variables included combination antiretroviral therapy era of diagnosis, CD4 cell count, and percentage time with undetectable HIV viral load...
October 23, 2016: AIDS
https://www.readbyqxmd.com/read/27749649/safety-and-efficacy-of-atorvastatin-in-human-immunodeficiency-virus-infected-children-adolescents-and-young-adults-with-hyperlipidemia
#19
Ann J Melvin, Grace Montepiedra, Lisa Aaron, William A Meyer, Hans M Spiegel, William Borkowsky, Mark J Abzug, Brookie M Best, Marilyn J Crain, Peggy R Borum, Bobbie Graham, Patricia Anthony, Katherine Shin, George K Siberry
BACKGROUND: Human immunodeficiency virus (HIV)-infected children receiving antiretroviral therapy (ART) have increased prevalence of hyperlipidemia and risk factors for cardiovascular disease. No studies have investigated the efficacy and safety of statins in this population. METHODS: HIV-infected youth 10 to <24 years of age on stable ART with low-density lipoprotein cholesterol (LDL-C) ≥130 mg/dL for ≥6 months initiated atorvastatin 10 mg once daily...
January 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/27720238/-cross-sectional-study-of-comorbidities-and-concomitant-medications-in-a-cohort-of-human-immunodeficiency-virus-infected-patients
#20
Maria Asunción García Gonzalo, María Isabel Santamaría Mas, Lidia Pascual Tomé, Maialen Ibarguren Pinilla, Francisco Rodríguez-Arrondo
AIM: To assess the prevalence of comorbidities, concomitant therapies and adverse effects associated with the medication in a cohort of patients with HIV infection. DESIGN: Multicentre cross-sectional study. SETTINGS: Infectious Diseases or Internal Medicine outpatient Clinics of 3 hospitals in the Basque Country. PARTICIPANTS: During a 3 month period, patients with the following inclusion criteria were randomly selected: HIV infection, age>18years, antiretroviral treatment (ART) for at least 6months, and no changes in ART in the previous 4weeks...
October 5, 2016: Atencion Primaria
keyword
keyword
14751
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"